中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
9期
1150-1152
,共3页
耐多药鲍曼不动杆菌肺炎%头孢哌酮/舒巴坦%替加环素%亚胺培南/西司他丁%临床疗效
耐多藥鮑曼不動桿菌肺炎%頭孢哌酮/舒巴坦%替加環素%亞胺培南/西司他丁%臨床療效
내다약포만불동간균폐염%두포고동/서파탄%체가배소%아알배남/서사타정%림상료효
Multidrug-resistant acinetobacter baumannii pneumonia%Cefoperazone/sulbactam%Tigecycline%Imipenem/Cilastatin%Clinical efficacy
目的：对比观察头孢哌酮／舒巴坦与亚胺培南／西司他丁、头孢哌酮／舒巴坦与替加环素联合治疗耐多药鲍曼不动杆菌（ multidrug-resistant acinetobacter baumannii ，MDRAB）肺炎的临床疗效，为临床用药提供参考。方法：选取MDRAB肺炎患者120例，以随机数字表法分为观察组与对照组各60例。观察组患者给予头孢哌酮／舒巴坦（3.0 g、每6 h给药1次）联合替加环素（50 mg，首剂加倍、每12 h给药1次）静脉滴注，对照组患者给予头孢哌酮／舒巴坦（3.0 g、每6 h给药1次）联合亚胺培南／西司他丁（1 g、每8 h给药1次）静脉滴注，疗程10～14 d，比较2组患者的临床疗效。结果：观察组患者的痊愈率为86.67％（52／60）、总有效率为96.67％（58／60），均明显高于对照组患者的56.67％（34／60）、76.67％（46／60），差异均有统计学意义（P＜0.05）。结论：头孢哌酮／舒巴坦与替加环素联合治疗MDRAB肺炎的临床疗效优于头孢哌酮／舒巴坦与亚胺培南／西司他丁联合治疗。
目的：對比觀察頭孢哌酮／舒巴坦與亞胺培南／西司他丁、頭孢哌酮／舒巴坦與替加環素聯閤治療耐多藥鮑曼不動桿菌（ multidrug-resistant acinetobacter baumannii ，MDRAB）肺炎的臨床療效，為臨床用藥提供參攷。方法：選取MDRAB肺炎患者120例，以隨機數字錶法分為觀察組與對照組各60例。觀察組患者給予頭孢哌酮／舒巴坦（3.0 g、每6 h給藥1次）聯閤替加環素（50 mg，首劑加倍、每12 h給藥1次）靜脈滴註，對照組患者給予頭孢哌酮／舒巴坦（3.0 g、每6 h給藥1次）聯閤亞胺培南／西司他丁（1 g、每8 h給藥1次）靜脈滴註，療程10～14 d，比較2組患者的臨床療效。結果：觀察組患者的痊愈率為86.67％（52／60）、總有效率為96.67％（58／60），均明顯高于對照組患者的56.67％（34／60）、76.67％（46／60），差異均有統計學意義（P＜0.05）。結論：頭孢哌酮／舒巴坦與替加環素聯閤治療MDRAB肺炎的臨床療效優于頭孢哌酮／舒巴坦與亞胺培南／西司他丁聯閤治療。
목적：대비관찰두포고동／서파탄여아알배남／서사타정、두포고동／서파탄여체가배소연합치료내다약포만불동간균（ multidrug-resistant acinetobacter baumannii ，MDRAB）폐염적림상료효，위림상용약제공삼고。방법：선취MDRAB폐염환자120례，이수궤수자표법분위관찰조여대조조각60례。관찰조환자급여두포고동／서파탄（3.0 g、매6 h급약1차）연합체가배소（50 mg，수제가배、매12 h급약1차）정맥적주，대조조환자급여두포고동／서파탄（3.0 g、매6 h급약1차）연합아알배남／서사타정（1 g、매8 h급약1차）정맥적주，료정10～14 d，비교2조환자적림상료효。결과：관찰조환자적전유솔위86.67％（52／60）、총유효솔위96.67％（58／60），균명현고우대조조환자적56.67％（34／60）、76.67％（46／60），차이균유통계학의의（P＜0.05）。결론：두포고동／서파탄여체가배소연합치료MDRAB폐염적림상료효우우두포고동／서파탄여아알배남／서사타정연합치료。
OBJECTIVE:To compare and observe the clinic efficacy of cefoperazone/sulbactam respectively combined with tigecycline and imipenem/cilastatin in treatment of multidrug-resistant acinetobacter baumannii ( MDRAB) pneumonia , and to provide reference for the clinic use of drug .METHODS: 120 patients with MDRAB pneumonia were selected to be divided into observation group and control group via the random number table , with 60 cases in each group .The observation group were treated with cefoperazone/sulbactam ( 3.0 g, 6 h/1 times ) combined with tigecycline(50 mg,first dose doubling, 12 h/1 times)in intravenous drip;the control group received cefoperazone/sulbactam(3.0 g, 6 h/1 times)combined with imipenem/cilastatin(1 g, 8 h/1 times)in intravenous drip, the treatment course was 10-14 d, the clinic efficacy were compared between two groups .RESULTS: In the observation group , the recovery rate was 86.67%( 52/60 ) , the effective rate was 96.67%( 58/60 ) , both of which were significantly higher than that in control group [ 56.67%( 34/60 ) , 76.67%( 46/60 ) ] , the difference between the two groups was statistically significant (P<0.05).CONCLUSIONS:The clinic efficacy of cefoperazone/sulbactam combined with tigecycline are better than that with the imipenem /cilastatin in treatment of MDRAB pneumonia .
